Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02857270 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
NCT02857270: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT02857270 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 210 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02857270, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
Interventions
- DRUG Midazolam
- DRUG Abemaciclib
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG LY3214996
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2016-09-29 |
| Est. Completion | 2022-10-24 |
| Phase | Phase 1 |
What the finished NCT02857270 record still lists
NCT02857270 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (250% higher).
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT02857270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02857270 about?
NCT02857270 is a clinical study titled "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer". The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
What is the current status of trial NCT02857270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2016-09-29. Estimated completion is 2022-10-24.
What interventions are being tested in trial NCT02857270?
The interventions under investigation include: Midazolam (DRUG), Abemaciclib (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), LY3214996 (DRUG).
Who is sponsoring clinical trial NCT02857270?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02857270's enrollment target sits among peer trials
210 245th of 2000 higher than 1,751 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI